1 Article Title: Infectious Complications Following CD30 Chimeric Antigen Receptor T-Cell Therapy

- 2 in Adults
- 3 Short Title: Infections After CD30.CAR T-Cell Therapy
- 4

14 15

16 17

18 19 20

- Authors: Felicia Cao^{*1}, Yueling Xiu^{*2}, Michael Mohnasky^{*3}, Jonathan S. Serody^{4,5}, Paul Armistead^{4,5},
- 5 6 Gianpietro Dotti^{5,6}, Melody Smith⁷, Jonathan Huggins⁸, Julia Messina⁸, Bhanu Ramachandran⁹, Jennifer
- 7 Saullo⁸, Joseph Stromberg⁹, Manish K. Saha¹⁰, Megan Walsh³, Barbara Savoldo^{5,11}, Natalie Grover^{4,5},
- Heather I. Henderson**⁹, and Tessa M. Andermann**^{5,9} 8
- 9 *Co-first authors
- 10 **Co-senior authors 11

12 **Affiliations:** 13

¹ Divisions of Hematology and Oncology, Department of Medicine, University of North Carolina at Chapel Hill, North Carolina, USA

²Gillings School of Public Health, University of North Carolina at Chapel Hill, North Carolina, USA

³School of Medicine, University of North Carolina at Chapel Hill, North Carolina, USA

⁴Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, North Carolina, USA

⁵Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

⁶Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, North Carolina. USA

⁷Division of Blood & Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, California, USA

⁸Division of Infectious Diseases, Department of Medicine, Duke University, North Carolina, USA

 $\begin{array}{c} 21\\ 22\\ 23\\ 24\\ 25\\ 22\\ 22\\ 22\\ 23\\ 31\\ 23\\ 33\\ 35\\ 37\\ 35\\ 37\\ \end{array}$ ⁹Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, North Carolina, USA

¹⁰Division of Nephrology, Department of Medicine, University of North Carolina at Chapel Hill, North Carolina, USA

38 39 40 ¹¹Division of Hematology-Oncology, Department of Pediatrics, University of North Carolina at Chapel 41 Hill, North Carolina, USA

43 **Corresponding Author:**

- 44 Tessa Andermann
- 45 111 Mason Farm Rd. Cb#7036
- 46 Medical Biomolecular Research Building #2340-B
- 47 Chapel Hill, NC 27599-7036
- 48 Tessa andermann@med.unc.edu
- 49 (919) 843-0834
- 50

- 51 Word Count (text): 3892
- 52 Word Count (abstract): 250
- 53 Figure/Table Count: 7 (4 supplementary)
- 54 Reference Count: 29

55 ABSTRACT

56 Infections are increasingly recognized as a common complication of chimeric antigen receptor (CAR) T-57 cell therapy. The incidence of clinically-defined infection after CD19.CAR T-cell therapy for 58 relapsed/refractory lymphoma ranges from 60-90% in the first year after CAR T-cell therapy and is the 59 most common cause for non-relapse mortality. However, infectious risk after CAR T-cell therapy 60 targeting other malignancies is not well understood. Herein, we report for the first time, infectious 61 complications after CD30.CAR T-cell treatment for patients with Hodgkin's lymphoma and peripheral T-62 cell lymphoma. Since CD30 is only expressed on a subset of activated T and B-cells, we hypothesized 63 that CD30.CAR T-cell patients would have reduced incidence and severity of infections after infusion 64 compared to CD19.CAR T-cell patients. We retrospectively evaluated all 64 patients who received 65 CD30.CAR T-cells at a single institution between 2016-2021, and assessed infections within one year 66 after cell infusion, comparing these data to a contemporary cohort of 50 patients who received 67 CD19.CAR T-cells at the same institution between 2018-2021, 23 CD30.CAR T-cell patients (36%) and 68 18 CD19.CAR T-cell patients (36%) developed a microbiologically confirmed infection. Infection 69 severity and bacterial infections were higher in the CD19.CAR T-cell group compared to CD30.CAR T-70 cell recipients who more commonly had grade 1 respiratory viral infections. Our data reflect expected 71 outcomes for severity and infection type in CD19.CAR T-cell patients and provide a benchmark for 72 comparison with the novel CD30.CAR T-cell product. Although our findings require replication in a 73 larger cohort, they have implications for antimicrobial prophylaxis guidelines after CD30.CAR T-cell 74 therapy.

77 KEY POINTS

78 79

80

81

- 1) The incidence of infections within the first year after CD30.CAR T-cell therapy was equivalent to that following CD19.CAR T-cell therapy
- 2) Viral infections were more common after CD30.CAR T-cell therapy but bacterial infections predominated after CD19.CAR T-cell therapy.

84 **INTRODUCTION**

85 Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed and

- 86 refractory hematological malignancies. The first FDA approved CAR T-cells targeted CD19, a surface
- 87 glycoprotein expressed on all B cells, for treatment of B cell malignancies including leukemia and
- 88 lymphoma¹. CD19.CAR T-cells are now the standard of care for patients with aggressive non-Hodgkin's
- lymphoma who have progressed after two prior lines of therapy $^{2-6}$. 89
- 90
- 91 Commonly recognized side effects of CAR T-cell treatment include cytokine release syndrome (CRS)
- 92 and immune effector cell associated neurotoxicity (ICANS)^{7,8}. However, infections are increasingly being
- 93 recognized as common, and often severe, complications following CAR T-cell therapy. Infections are the
- 94 most frequent cause of non-relapse related mortality after CD19.CAR T-cell therapy for patients with
- 95 non-Hodgkin's lymphoma^{9,10}. The incidence of clinically-defined infections after CD19.CAR T-cell
- 96 treatment ranged from 60 to 90% within one-year post-infusion, with 15-30% of infections being severe
- 97 or life-threatening⁹⁻¹². Infections were most commonly seen in the first month post CD19.CAR T-cell
- 98 infusion, with the highest incidence of bacterial infections during this time period. Factors associated with
- 99 infectious risk following CD19.CAR T-cell therapy included incidence of CRS/ICANS and corticosteroid
- 100 use^{9–11}. The CAR-HEMATOTOX model has been proposed to risk stratify patients treated with
- 101 CD19.CAR T-cells who are at highest risk for hematotoxicity and severe infectious complications due to
- 102 delayed hematopoietic recovery¹³.
- 103
- 104 In contrast, CD30 is transiently expressed by subsets of activated T and B cells and is highly expressed on hematological malignancies including Hodgkin's lymphoma and anaplastic large cell lymphoma¹⁴⁻¹⁶. 105 106 Brentuximab vedotin is a CD30 directed antibody-drug conjugate (ADC) that has been approved for treatment of patients with relapsed or refractory Hodgkin's lymphoma^{17,18}. Our group in a multi-center 107 108 study characterized the outcome of patients, receivingCD30.CAR T-cell therapy and found an overall 109 response rate (ORR) of 72% for the treatment of patients with relapsed/refractory Hodgkin lymphoma at 6 weeks post-treatment, with 36% progression-free survival over one year¹⁹. Another ongoing clinical
- 111 trial is evaluating efficacy of CD30.CAR T-cells for patients with relapsed/refractory peripheral T-cell
- 112 lymphoma (NCT04083495).
- 113

- 114 The patient population receiving CD30.CAR T-cell therapy differs substantially from CD19.CAR T-cell
- 115 therapy, as Hodgkin's lymphoma tends to affect younger patients who receive less cytotoxic
- chemotherapy and more ADC or immunotherapy based treatments^{20,21}. Infectious risk after CD30.CAR T-116
- 117 cell therapy has not previously been characterized, including types of infections and their severity after

- 118 CD30.CAR T-cell infusion. Currently, antimicrobial prophylaxis for any CAR T-cell treatment is based
- 119 on existing guidelines for patients receiving CD19.CAR T-cells, although little data exists to inform
- 120 prophylaxis after CAR T-cell treatments targeting different antigens^{22,23}. Herein, we sought to
- 121 characterize infectious risk during the first year after CD30.CAR T-cell infusion, benchmarked against
- 122 infectious outcomes following CD19.CAR T-cell therapy, in order to more appropriately tailor
- 123 antimicrobial prophylaxis for our patients.
- 124
- 125 METHODS
- 126 Patient cohort
- 127 Patients in this study were adults ≥ 18 years of age at the University of North Carolina at Chapel Hill
- 128 (UNCCH) with relapsed or refractory CD30+ lymphomas as part of clinical trials NCT02690545,
- 129 NCT03602157, NCT04083495, and NCT02663297. Of note, NCT02663297 investigated CD30.CAR T-
- 130 cell infusion as consolidation after autologous stem cell transplant for CD30+ lymphoma (16 patients in
- this study)²⁴. All patients who received CD30.CAR T-cell therapy from July 1, 2016 through July 31,
- 132 2021 were included in this retrospective review. For comparison, we included all adult patients \geq 18 years
- 133 of age at UNCCH who received CD19.CAR T-cells either as a commercial product or as part of a clinical
- trial (NCT03016377, NCT03696784, or NCT03594162) from April 1, 2018 through November 30, 2021.
- 135 Consent was not required for inclusion in this study but was required for treatment with CD30.CAR T-
- 136 cells. Approval was obtained from the UNCCH institutional review board (IRB#20-2745, PI:
- 137 Andermann).
- 138

139 *Treatment and prophylaxis*

- 140 Manufacture of CD30.CAR T-cells was performed as described previously¹⁹. Patients received 1-200 x
- 141 10^6 CD30 targeted CAR-T cells for relapsed or refractory disease following lymphodepleting
- 142 chemotherapy. Patients enrolled in NCT03602157 (12 patients) received CD30.CAR T-cells and
- 143 additional T-cells co-expressing CD30.CAR and C-C Motif Chemokine Receptor 4 (CCR4). The majority
- 144 of patients received antimicrobial prophylaxis consisting of valacyclovir 500mg daily or twice daily per
- 145 provider preference and trimethoprim/sulfamethoxazole 160mg/800mg once per day, three times per
- 146 week, starting at lymphodepletion (valacyclovir) or at day+30 (trimethoprim-sulfamethoxazole) until 6
- 147 months to one-year post-infusion or CD4 \geq 200. Patients also received neutropenia prophylaxis with
- 148 levofloxacin 500mg daily and fluconazole 400mg daily when absolute neutrophil count (ANC) \leq 500 cells
- 149 per mm2. The severity of CRS and ICANS were graded as described previously²⁵. Patients with grade ≥ 2
- 150 CRS or ICANS were treated with tocilizumab (8mg/kg per dose IV) and/or corticosteroids as per
- 151 institutional standards and previously published guidelines 25 .

152

153 *Data collection and infection definitions*

154 Patient information was manually extracted from the electronic medical record and entered into a

- 155 REDCap database by at least two independent reviewers (M.M., F.C., J.S., M.S., B.R.). Discrepancies
- between reviewers were resolved through adjudication by the primary study investigator (T.M.A.).
- 157 Information regarding infections and antibiotics was abstracted starting 30 days prior through 365 days
- 158 after CAR T-cell infusion. When censoring events were considered in select figures, patients were
- 159 censored at relapse, next line of treatment, or at last contact with UNCCH.
- 160

161 Only microbiologically determined infections were included in this study, based on a positive culture or

162 diagnostic test. One exception to this definition was the diagnosis of dermatomal Varicella Zoster Virus

163 (VZV) which was included without an available positive diagnostic test if presentation met criteria as

164 determined by the treating clinician. Bloodstream infections were adjudicated based on CDC/NHSN

165 criteria²⁶. Upper respiratory tract infections were based on clinical judgement and the absence of an

166 oxygen requirement or infiltrates on chest imaging; lower respiratory tract infections were defined by

167 infiltrates on chest imaging and lower respiratory tract symptoms. Infection severity was defined as mild

168 (Grade 1), moderate (Grade 2), or severe (Grade 3) based on previously published Blood & Marrow

169 Transplant Clinical Trials Network (BMT-CTN) 2023 criteria²⁷.

170

171 *Statistical analysis*

172 Continuous variables are reported as median and range; categorical variables are reported as number and173 percentage. For comparing characteristics between patients with and without infections, the Kruskal-

· · ·

174 Wallis test was used for continuous variables and Fisher's exact test was used for categorical variables.

175 The association between risk factors and time to infection among CD30.CAR T-cell patients was

176 estimated using Fine-Gray subdistribution hazard models, treating all-cause mortality as a competing

177 event²⁸. ANC of 1.8 cells/mm² was used as cut-off based on the institutional laboratory reference range.

178 Age was modeled as a second-degree polynomial after evaluating its functional form in relation to

179 infection risk. In cumulative-incidence curves, patients contributed time from the date of infusion until the

180 earliest of the following: first infection (overall and stratified by pathogen type), death, or administrative

181 censoring at 365 days post-infusion. As a secondary analysis, patients were censored if relapse occurred

182 within one year after infusion. P-values less than 0.05 were considered statistically significant. Analyses

183 were performed using R software version 4.3.2, with the *cmprsk* package used to estimate the cumulative

184 incidence of infection.

186 **RESULTS**

187 Patient characteristics

188 Sixty-four adult patients received CD30.CAR T-cells at the University of North Carolina at Chapel Hill 189 (UNCCH) from 2016 to 2021 (Table 1). Fifty patients (78%) had Hodgkin's lymphoma (HL) and 14 190 patients (22%) had peripheral T-cell lymphoma. Patient characteristics for CD30.CAR T-cell treated 191 patients are described in **Table 1**, stratified by infection status. The median age was 40.9 (range 18 to 77) 192 years. This was a heavily pre-treated patient population, with patients receiving a median of four lines of 193 therapy (range 2 to 17) prior to CAR T-cell therapy. Fifty-six patients (88%) had received a 194 hematopoietic stem cell transplantation (HSCT) prior to CAR T-cell treatment, with the vast majority 195 being autologous transplants. 196 197 For comparison, we included the cohort of all 50 patients treated with CD19.CAR T-cells at UNCCH 198 from 2018 to 2021 (Supplementary Table S1). Twelve patients within this group (24%) had acute 199 lymphoblastic leukemia (ALL), 30 (60%) had diffuse large B-cell lymphoma (DLBCL), and eight (16%) 200 had follicular lymphoma or mantle cell lymphoma. The median age was 60.6 (range 21 to 81) years. 201 Similar to the CD30.CAR T-cell therapy cohort, patients were heavily pre-treated, having received a 202 median of four (range 2 to 12) prior treatment lines. The proportion of those receiving CD19.CAR T-cells 203 who had received a prior HSCT (14 patients, 28%) was lower compared to those receiving a CD30 204 product at our institution.

205

The incidence of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity
 syndrome (ICANS) was lower in the CD30.CAR T-cell cohort (Table 1) compared to the CD19.CAR T-

208 cell cohort (Supplementary Table S1). Sixteen patients (25%) who received CD30.CAR T-cells

experienced CRS of any grade, with only five patients (8%) demonstrating Grade 2 CRS, and none with

210 Grade 3 or higher CRS. No patients were diagnosed with ICANS after CD30.CAR T-cell infusion. In

contrast, 34 patients (68%) in the CD19.CAR T-cell group developed CRS of any grade, with 16 patients

212 (32%) who developed Grade 2 CRS and one patient (2%) who developed Grade 3 CRS. 14 patients (28%)

- 213 developed ICANS after CD19.CAR T-cell therapy.
- 214

215 Incidence of infections after CAR T-cell therapy

216 Twenty-three patients (36%) developed a microbiologically confirmed infection within one year after

217 CD30.CAR T-cell therapy. The cumulative incidence of all infections within one year after CD30.CAR

218 T-cell treatment is shown in Figure 1. Six bacterial infections, 21 viral infections, and one fungal

219 infection were seen in 23 CD30.CAR T-cell patients. When censoring for relapse, three bacterial

infections and 16 viral infections were reported in 16 CD30.CAR T-cell patients (Supplementary Figure
S1). No fungal infections were observed after censoring for relapse.

222

223 In comparison, the same proportion of CD19.CAR T-cell patients (n=18, 36%) developed an infection

within one year from cell infusion (Figure 1). Eighteen bacterial infections, 12 viral infections, and three

fungal infections were reported in 18 infected CD19.CAR T-cell patients. When censoring for relapse,

- seven bacterial infections and six viral infections were reported in 10 patients (Supplementary Figure
- 227 S1).
- 228

229 The incidence of bacterial, viral, and fungal infections from days 0-28, days 29-90, and days 91-365 for 230 CD30 and CD19.CAR T-cell patients are shown in Figure 2. In the CD30.CAR T-cell cohort, viral 231 infections were more common than bacterial infections at all timepoints. This contrasts with CD19.CAR 232 T-cell patients, in which bacterial infections were more common than viral infections, most prominently 233 in the first 28 days after CAR T-cell infusion. This difference holds even when censoring for relapse 234 (Supplementary Figure S1). Fungal infections were rare, occurring only in one patient who received 235 CD30.CAR T-cells and three patients who received CD19.CAR T-cells, and only in the setting of 236 relapsed disease. A list of causative infectious organisms is shown in **Table 2**, which again highlights that 237 viral infections were more common after CD30.CAR T-cell therapy, and bacterial infections are more 238 common after CD19.CAR T-cell treatment.

239

Notably, the incidence of infections was higher in patients with relapsed disease after day 90, as 13
infections were seen during this time in the CD30.CAR T-cell cohort and 22 infections in the CD19.CAR

242 T-cell cohort. However, this appears to correlate with disease recurrence as there were only five

243 infections that occurred in the CD30.CAR T-cell cohort and three infections in the CD19.CAR T-cell

cohort in non-relapsed patients. Nonetheless, similar to previously published data for CD19.CAR T-cell

therapy, patients receiving CD30.CAR T-cell therapy may be at increased risk for infectious complication

- for a prolonged period post-cell infusion, although bacterial infections were more common in the first 28
 days in both our data and prior literature⁹⁻¹².
- _ .,

248

249 Severity of infections after CAR T-cell therapy

250 To further understand the clinical relevance of infections seen after CAR T-cell therapy, the severity of

251 infections was assessed using BMT-CTN 2023 criteria²⁷. The severity of microbiologically confirmed

252 infections within one year after CD30 or CD19.CAR T-cell infusion is shown in Figure 3. Similar data,

253 censored for relapsed disease, are shown in **Supplementary Figure S2**. For CD30.CAR T-cell patients,

254 most infections were mild with three grade 1 bacterial infections and 18 grade 1 viral infections. Severe or

- 255 life-threatening infections were rare, with only one grade 3 bacterial infection and one grade 3 viral
- 256 infection found in the CD30.CAR T-cell cohort. When censoring for relapse within one year of
- 257 CD30.CAR T-cell infusion, only one grade 3 viral infection (of a total of 19 infections) remained.
- 258

In contrast, the CD19.CAR T-cell patients had more severe infections overall with four grade 3 bacterial infections but no severe or life-threatening viral infections. When censoring for relapse, there were two grade 3 bacterial infections (total n=13 infections) within one year of CD19.CAR T-cell infusion. These data demonstrate that overall severity of infection was lower in the CD30.CAR T-cell patients compared to the CD19.CAR T-cell cohort. In summary, most infections in the CD30.CAR T-cell group were caused by respiratory viral pathogens and were milder whereas more patients in the CD19.CAR T-cell group had

- bacterial infections with higher severity.
- 266

267 Factors associated with increased infectious risk

Baseline characteristics of the 23 patients who developed a microbiologically confirmed infection in the first year after CD30.CAR T-cell therapy were compared to the 41 patients who did not develop an infection in **Table 1**. In univariate analysis, the only baseline characteristic significantly different between these two groups was ANC at 30 days prior to cell infusion (p=0.004). After adjusting for age, ANC ≤ 1.8 cells/mm² at day -30 remained significantly associated with infection risk, with an adjusted hazard ratio (HR) of 3.4 (95% confidence interval [CI] 1.5 – 8.1). The small number of patients in our study limited

- 274 our ability to include additional covariates in our model.
- 275

276 Steroid use was not associated with increased infection risk in CD30.CAR T-cell patients, with 11

277 patients (48%) receiving steroids within a year of cell infusion in the infected group and 17 patients

278 (42%) receiving steroids within a year of cell infusion in the non-infected group. Steroid use was

279 generally low dose (less than or equivalent to 40mg prednisone daily) or a one-time single dose in the

280 CD30.CAR T-cell group; in this cohort, steroids were not used for treatment of CRS/ICANS, and instead

were given for a variety of indications including premedication prior to chemotherapy or surgery, or for

adrenal insufficiency. This contrasts with CD19.CAR T-cell patients, in which steroid use was mostly for

- treatment of CRS/ICANS and significantly associated with infection risk (p=0.02) (Supplementary
- **Table S1**). Steroid use was higher in the infected group, likely due to treatment for ICANS (n=9, 50%)
- compared to patients who had no infections (n=5, 15.6%, p=0.02 for infected v. non-infected). Notably,
- this same relationship between steroid use and infectious risk has been observed in prior studies in
- 287 CD19.CAR T-cell recipients^{10,11}. Infection-related mortality was a significant cause of death in the

- 288 CD19.CAR T-cell group, with 7 (63.6%) infection-related deaths and only 4 (36.5%) relapsed-related
- deaths in the infected group compared to 13 (86.7%) relapse-related deaths and 2 (13.3%) "other" causes
- of death in the non-infected group (p=0.004). Overall, these data show that CD19.CAR T-cell patients
- 291 have more measured variables associated with infection risk in univariate analysis compared to
- 292 CD30.CAR T-cell patients.
- 293

294 Immune reconstitution after CD30.CAR T-cell therapy

295 Given the significant association between day-30 ANC and infectious complications in CD30.CAR T 296 patients, we sought to better understand the trajectory of immune reconstitution after CD30.CAR T-cell 297 therapy. We examined the kinetics of absolute neutrophil and lymphocyte counts (ANC and ALC) 30 298 days prior to, and at multiple timepoints after, CAR T-cell infusion. Differences in ANC and ALC in 299 CD30.CAR T-cell patients with and without infections are shown in Figure 4. The nadir for ALC was on 300 day 0 of CAR T-cell infusion as expected, secondary to lymphodepleting chemotherapy. Surprisingly, the 301 nadir for ANC was seen on day 60, a finding which cannot be explained by lymphodepletion. There were 302 no significant differences in ANC and ALC between the infected and non-infected groups over time 303 except for a lower ANC 30 days prior (p=0.004) and at day 0 (p=0.01) in those receiving CD30.CAR T-304 cells who were infected. Similarly, when comparing ANC and ALC for infected and non-infected 305 CD19.CAR T-cell patients, there were no significant differences in ANC and ALC at most timepoints. 306 The only exceptions were for ANC at 9 months post-cell infusion (p=0.02) and ALC at 30 days prior to 307 cell infusion (p=0.04); in both instances, cell counts were higher in infected patients, a finding likely 308 spurious due to multiple testing.

309

310 There were significant differences seen when comparing ANC and ALC between CD30 and CD19.CAR

- 311 T-cell patients as seen in Figure 5. There was no difference in ANC and ALC 30 days prior to cell
- 312 infusion in the two cohorts. However, significant differences were seen at multiple timepoints on and
- after cell infusion. ANC was significantly lower in the CD19.CAR T-cell cohort compared to the
- 314 CD30.CAR T-cell group at every timepoint on or after cell infusion except at day 60 and 1 year. Similar
- results were seen for ALC, which was significantly lower in the CD19.CAR T-cell versus CD30.CAR T-
- cell cohort at every timepoint on or after cell infusion except for day +60. Of note, these statistical
- 317 comparisons were performed after removing CD30.CAR T-cell patients enrolled in clinical trial
- 318 NCT02663297, since an immediately preceding autologous HSCT may have influenced blood counts²⁴.
- 319 However, since the statistical trends were similar, all patient data was shown in the figure.
- 320

321 DISCUSSION

322 In these two cohorts of 114 patients in total treated with CD30 or CD19.CAR T-cells for

- 323 relapsed/refractory hematological malignancies, we found a similar incidence of microbiologically
- 324 confirmed infections within one year from cell infusion. Notably, when censoring for relapse, the
- incidence of infection was higher in CD30.CAR T-cell (27%) versus CD19.CAR T-cell recipients (16%).
- 326 Infections in the CD30.CAR T-cell cohort were primarily viral (versus bacterial in the CD19.CAR T-cell
- 327 group) and were less severe. As expected, for both groups, a greater proportion of infections were seen in
- 328 the initial 30-day period after cell infusion. Unexpectedly, the higher incidence of viral infections in the
- 329 CD30.CAR T-cell cohort is not related to lymphopenia, as ALC was significantly lower at most
- timepoints after CD19.CAR T-cell infusion compared to CD30.CAR T-cell therapy. Instead, ANC 30
- days prior to CAR T infusion was significantly lower in infected patients.
- 332

333 There were multiple differences between the two cohorts which may contribute to variability in infection 334 types and severity. Yet, the CD19.CAR T-cell treated cohort remains an appropriate benchmark for 335 comparison in our review of infection outcomes following CD30.CAR T-cell treatment, with results from our CD19 cohort similar to those published previously.⁹⁻¹² One important difference between the two 336 337 cohorts is the inclusion of a majority of patients with Hodgkin's lymphoma in the CD30 group, as these 338 patients tend to be younger at diagnosis. This was reflected in the lower median age for the CD30 339 compared to the CD19 cohort (40.9 v. 60.6 years). Additionally, most patients in the CD30 cohort had 340 received prior HSCT, including 29 total patients who received autologous HSCT within 90 days prior to 341 CD30.CAR T-cell therapy. Despite this additional immunosuppression in the CD30 group, infection risk 342 was much less frequent and less severe.

343

Antimicrobial prophylaxis use, including both antibacterials and antivirals, was similar between infected
and non-infected patients in both the CD30 and CD19.CAR T-cell cohorts, but overall higher in the
CD19.CAR T-cell treated patients (Tables 1 and Supplementary Table S1). We postulate this to be a

- 347 consequence of more standardized and increased antimicrobial prophylaxis use in patients post
- 348 CD19.CAR T-cell therapy (i.e., patients underwent CD30.CAR T-cell treatment starting 2 years earlier
- 349 (2016 v. 2018) than CD19.CAR T-cell patients). With regards to antiviral prophylaxis, five cases of VZV
- 350 infection were observed in CD30.CAR T-cell patients while none were in CD19.CAR T-cell patients.
- 351 This may be related to a higher proportion of patients on valacyclovir prophylaxis in the CD19 cohort as
- 352 four of the five patients who developed VZV reactivation were not on prophylaxis at time of infection.
- 353
- Another difference between the two cohorts was the incidence of CRS/ICANS, which was far less
 frequent and less severe in CD30.CAR T-cell patients. No patients developed ICANS after CD30.CAR T-

356 cell infusion compared to 28% of CD19.CAR T-cell patients. The difference in ICANS/CRS between the

- two cohorts could be an explanation for why steroid use was significantly linked with infections (p=0.02)
- in the CD19.CAR T-cell cohort but not in the CD30.CAR T-cell cohort (p=0.8) as overall high-dose
- 359 steroid use was much more common in the former (Table 1 and Supplementary Table S1).
- 360

361 Another complicating factor may be the differences in lymphodepletion regimens between the two 362 cohorts. The majority of CD30.CAR T-cell treated patients received fludarabine and bendamustine for 363 lymphodepletion (n=37, 57.8%) with other regimens consisting of fludarabine/cyclophosphamide (n=3, 364 4.7%), bendamustine (n=7, 10.9%), and autologous HSCT (n=16, 26.0%). In contrast, the majority of 365 CD19.CAR T-cell receiving patients were treated with fludarabine/cyclophosphamide (n=44, 88%) with 366 some patients receiving fludarabine/bendamustine (n=5, 10%) or bendamustine alone (n=1, 2%) as 367 alternative lymphodepletion regimens (Table 1 and Supplementary Table S1). Bendamustine use prior 368 to apheresis for CD19.CAR T-cell therapy has been associated with lower T-cell counts at apheresis.²⁹. 369 However, since ALC at multiple timepoints post infusion was lower in the CD19.CAR T-cell cohort, who 370 mostly did not receive bendamustine compared to CD30.CAR T-cell cohort, it seems unlikely that

- 371 lymphodepletion alone is enough to account for differences in infections and immune recovery.
- 372

373 Strengths of this study include a relatively large total cohort of 114 CAR T-cell recipients and inclusion 374 of only microbiologically confirmed infections, with far less between-clinician bias. To our knowledge, 375 this is the first report of infection incidence and severity for patients treated with CD30.CAR T-cell 376 therapy, broadening our understanding of the epidemiology of infectious risk post-CAR T-cell infusion. 377 Limitations include heterogeneous disease types that preclude direct comparison between cohorts, with 378 more than four different hematological malignancies represented (Hodgkin's lymphoma, DLBCL, ALL, 379 and peripheral T cell lymphoma). Lymphocyte subsets and immunoglobulin levels were not routinely 380 collected on patients, which limited our assessment of immune reconstitution after CAR T-cell treatment. 381 Also, the majority of patients returned to their local oncologist for follow-up after the first month after 382 CAR T-cell infusion. While this may have limited data collection, all outside medical records available to 383 the investigators were reviewed. Finally, the COVID-19 pandemic unfolded during the study duration, 384 which may have reduced follow-up and data collection for patients treated after March 2020. Increased 385 respiratory viral testing overall due to COVID-19 may have led to increased detection of 386 microbiologically confirmed viral infections. Yet this difference would not have explained the increased 387 number of viral infections after CD30.CAR T-cell therapy, as patients were assessed during similar time 388 periods after 2020. Notably, the incidence of COVID-19 was comparable between the two cohorts, with

389 six cases (9%) of COVID-19 in CD30.CAR T-cell patients and four cases (8%) in CD19.CAR T-cell

- 390 patients.
- 391
- 392 In conclusion, this is the first study to report infections after CD30.CAR T-cell therapy for
- 393 relapsed/refractory Hodgkin's lymphoma or peripheral T-cell lymphoma. Identification of reduced ANC
- 394 prior to CD30.CAR T-cell infusion as a significant factor for infections after cell infusion may serve as a
- 395 marker for identifying patients at higher risk for infection, although further investigation is needed to
- 396 replicate these findings in a larger cohort. Given differences in infection risk following treatment,
- 397 CD30.CAR T-cell treated patients may not benefit as much from antibacterial prophylaxis as much as
- they might from prophylactic valacyclovir for prevention of HSV and VZV. Additional studies on the
- infectious risk of novel CAR T-cell therapies are needed with the potential to identify patients at highest
- 400 risk of developing infections and to tailor antimicrobial prophylaxis after CAR T-cell treatment.
- 401

402 Acknowledgements

- 403 The authors would like to acknowledge the staff of the University of North Carolina Chapel Hill and
- 404 UNC Hospitals, in particular the staff and patients at the Lineberger Cancer Center.
- 405
- 406 This work was supported in part by the following: F.C. is funded by National Cancer Institute UNC
- 407 Immunotherapy Training Grant T32 1T32CA28527-01. MM is funded by the Infectious Disease Society
- 408 of America Grants for Emerging Researchers (G.E.R.M). TMA is funded by the Amy Strelzer
- 409 Manasevit/Be The Match Foundation Award, a K23 NIAID/NIH Career Development Award
- 410 (AI163365), and the UNC Center for Gastrointestinal Biology and Disease pilot award. REDCap use was
- 411 made possible through grant UL1TR002489 from the Clinical and Translational Science Award program
- 412 of the Division of Research Resources, NIH. J.S.S. is supported by R01 155098 from NHLBI.
- 413

414 Authorship Contributions

- 415 T.M.A., M.S., J.H., J.M., and N.G. conceived of and designed the study with feedback from J.S.S., P.A.,
- 416 G.D., and B.S. who interpreted the data. T.M.A., F.C., M.M., J.S., M.K.S., and B.R. reviewed and
- 417 collected data from electronic health records and assisted in constructing the tables and figures. Y.X. and
- 418 H.H. performed the statistical analysis for the project and created the tables and figures. T.M.A. and F.C.,
- 419 wrote the manuscript with significant help from M.M. All authors contributed to the editing of the
- 420 manuscript and approved the final version.
- 421

422 Conflicts of Interest

- 423 J.S.S. has IP for the use of ILC2 cells to treat and prevent GVHD and for the use of STING agonists to
- 424 enhance CAR T-cell function; he receives royalty payments from Tessa Therapeutics for the CD30.CAR
- 425 T-cell product. G.D. has acted as a consultant of Bellicum Pharmaceutical and Tessa Therapeutics, serves
- 426 as a consultant for Catamaran, and has pending patents in the field of CAR T-cells. M.K.S. receives
- 427 honoraria from Calliditas, Travere, ChemoCentryx, and Elsevier. B.S. acted as a consultant of Tessa
- 428 Therapeutics. N.S.G. has served on an advisory board or consulted for Novartis, Kite, Seagen, ADC
- 429 Therapeutics, BMS, and Caribou Biosciences. T.M.A. serves as a consultant for Seres Therapeutics.
- 430 Otherwise, the remaining authors declare no conflicts of interest.
- 431
- 432

433 **REFERENCES**

- 435
 1. Scheuermann RH, Racila E. CD19 Antigen in Leukemia and Lymphoma Diagnosis and Immunotherapy. *Leuk Lymphoma*. 1995;18(5-6):385-397. doi:10.3109/10428199509059636
- 437
 2. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory
 438
 438 Large B-Cell Lymphoma. *N Engl J Med.* 2017;377(26):2531-2544. doi:10.1056/NEJMoa1707447
- 439 3. Schuster Stephen J., Bishop Michael R., Tam Constantine S., et al. Tisagenlecleucel in Adult Relapsed
 440 or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med*. 2019;380(1):45-56.
 441 doi:10.1056/NEJMoa1804980
- 442 4. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
 444 *The Lancet.* 2020;396(10254):839-852. doi:10.1016/S0140-6736(20)31366-0
- 5. Locke Frederick L., Miklos David B., Jacobson Caron A., et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. *N Engl J Med.* 2022;386(7):640-654.
 doi:10.1056/NEJMoa2116133
- Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with
 salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in
 patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim
 analysis of an open-label, randomised, phase 3 trial. *The Lancet*. 2022;399(10343):2294-2308.
 doi:10.1016/S0140-6736(22)00662-6
- 453 7. Santomasso B, Bachier C, Westin J, Rezvani K, Shpall EJ. The Other Side of CAR T-Cell Therapy:
 454 Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden. *Am Soc Clin Oncol Educ*455 *Book*. 2019;(39):433-444. doi:10.1200/EDBK_238691
- 8. Frigault MJ, Amoloja T, Burke LM, et al. Rates of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) from Center for International Blood and Marrow Transplant Research (CIBMTR) data on US subjects (SUBJ) with lymphoma following chimeric antigen receptor T cell therapy (CAR-T). *J Clin Oncol.* 2023;41(16_suppl):7528-7528. doi:10.1200/JCO.2023.41.16_suppl.7528
- 461
 9. Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor– modified T-cell immunotherapy. *Blood*. 2018;131(1):121-130. doi:10.1182/blood-2017-07-793760
- 463 10.Wudhikarn K, Palomba ML, Pennisi M, et al. Infection during the first year in patients treated with
 464 CD19 CAR T cells for diffuse large B cell lymphoma. *Blood Cancer J*. 2020;10(8):79.
 465 doi:10.1038/s41408-020-00346-7
- 466 11.Zhu F, Wei G, Liu Y, et al. Incidence and Risk Factors Associated with Infection after Chimeric
 467 Antigen Receptor T Cell Therapy for Relapsed/Refractory B-cell Malignancies. *Cell Transplant*.
 468 2021;30:09636897211025503. doi:10.1177/09636897211025503
- 469 12.Reynolds GK, Sim B, Spelman T, et al. Infections in haematology patients treated with CAR-T
 470 therapies: A systematic review and meta-analysis. *Crit Rev Oncol Hematol*. 2023;192:104134.
 471 doi:10.1016/j.critrevonc.2023.104134

- 472 13.Rejeski K, Perez A, Sesques P, et al. CAR-HEMATOTOX: a model for CAR T-cell-related
 473 hematologic toxicity in relapsed/refractory large B-cell lymphoma. *Blood*. 2021;138(24):2499-2513.
 474 doi:10.1182/blood.2020010543
- 475 14.Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1
 476 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic
 477 malignancies are derived from activated lymphoid cells. *Blood*. 1985;66(4):848-858.
- 478 15.Sabattini E, Pizzi M, Tabanelli V, et al. CD30 expression in peripheral T-cell lymphomas.
 479 *Haematologica*. 2013;98(8):e81-e82. doi:10.3324/haematol.2013.084913
- 480 16.van der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM. Understanding CD30 biology
 481 and therapeutic targeting: a historical perspective providing insight into future directions. *Blood*482 *Cancer J*. 2017;7(9):e603-e603. doi:10.1038/bcj.2017.85
- 483 17.Younes A, Gopal AK, Smith SE, et al. Results of a Pivotal Phase II Study of Brentuximab Vedotin for
 484 Patients With Relapsed or Refractory Hodgkin's Lymphoma. *J Clin Oncol.* 2012;30(18):2183-2189.
 485 doi:10.1200/JCO.2011.38.0410
- 486 18.Lai C, Kandahari AM, Ujjani C. The Evolving Role of Brentuximab Vedotin in Classical Hodgkin
 487 Lymphoma. *Blood Lymphat Cancer Targets Ther*. 2019;9:63-71. doi:10.2147/BLCTT.S231821
- 488 19.Ramos CA, Grover NS, Beaven AW, et al. Anti-CD30 CAR-T Cell Therapy in Relapsed and
 489 Refractory Hodgkin Lymphoma. *J Clin Oncol Off J Am Soc Clin Oncol*. 2020;38(32):3794-3804.
 490 doi:10.1200/JCO.20.01342
- 491 20.Paunescu AC, Copie CB, Malak S, et al. Quality of life of survivors 1 year after the diagnosis of
 492 diffuse large B-cell lymphoma: a LYSA study. *Ann Hematol.* 2022;101(2):317-332.
 493 doi:10.1007/s00277-021-04689-4
- 494 21.Kreissl S, Müller H, Goergen H, et al. Health-Related Quality of Life in Patients With Hodgkin
 495 Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group. *J Clin Oncol.*496 2020;38(25):2839-2848. doi:10.1200/JCO.19.03160
- 497 22.Haidar G, Garner W, Hill JA. Infections after anti-CD19 chimeric antigen receptor T-cell therapy for
 498 hematologic malignancies: timeline, prevention, and uncertainties. *Curr Opin Infect Dis.*499 2020;33(6):449-457. doi:10.1097/QCO.000000000000679
- 500 23.Wudhikarn K, Perales MA. Infectious complications, immune reconstitution, and infection
 501 prophylaxis after CD19 chimeric antigen receptor T-cell therapy. *Bone Marrow Transplant*.
 502 2022;57(10):1477-1488. doi:10.1038/s41409-022-01756-w
- 503 24.Grover NS, Hucks G, Riches ML, et al. Anti-CD30 CAR T cells as consolidation after autologous
 504 haematopoietic stem-cell transplantation in patients with high-risk CD30+ lymphoma: a phase 1 study.
 505 *Lancet Haematol.* 2024;11(5):e358-e367. doi:10.1016/S2352-3026(24)00064-4
- 506 25.Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release
 507 Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. *Biol Blood Marrow* 508 *Transplant*. 2019;25(4):625-638. doi:10.1016/j.bbmt.2018.12.758

- 509 26.Tomlinson D, Mermel LA, Ethier MC, Matlow A, Gillmeister B, Sung L. Defining bloodstream
 510 infections related to central venous catheters in patients with cancer: a systematic review. *Clin Infect*511 *Dis Off Publ Infect Dis Soc Am.* 2011;53(7):697-710. doi:10.1093/cid/cir523
- 512 27.Shahid Z, Etra AM, Levine JE, et al. Defining and Grading Infections in Clinical Trials Involving
 513 Hematopoietic Cell Transplantation: A Report From the BMT CTN Infectious Disease Technical
 514 Committee. *Transplant Cell Ther Off Publ Am Soc Transplant Cell Ther*. 2024;30(5):540.e1-540.e13.
 515 doi:10.1016/j.jtct.2024.03.001
- 516 28.Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am
 517 Stat Assoc. 1999;94(446):496-509. doi:10.2307/2670170
- 518 29.Iacoboni G, Navarro V, Martín-López AÁ, et al. Recent Bendamustine Treatment Before Apheresis
 519 Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric
 520 Antigen Receptor T-Cell Therapy. *J Clin Oncol Off J Am Soc Clin Oncol*. 2024;42(2):205-217.
 521 doi:10.1200/JCO.23.01097

TABLES AND FIGURES

Table 1. Demographics and treatment-related complications of patients with and without microbiologically confirmed infections within one year after anti-CD30 CAR-T therapy.

	Infected*	Not infected	Total	p- value
	N= 23	N = 41	N = 64	
Median age [range]	36.3 [18.0, 75.7]	41.3 [20.1, 77.0]	40.9 [18.0, 77.0]	0.894
Sex (male), n (%)	13 (56.5)	29 (70.7)	42 (65.6)	0.382
Race, n (%)				0.109
Caucasian	20 (87.0)	30 (73.2)	50 (78.1)	
African American	3 (13.0)	4 (9.8)	7 (10.9)	
Other	0 (0.0)	7 (17.1)	7 (10.9)	
Ethnicity, n (%)				0.218
Hispanic	0 (0.0)	1 (2.4)	1 (1.6)	
Non-Hispanic	23 (100.0)	36 (87.8)	59 (92.2)	
Unknown	0 (0.0)	4 (9.8)	4 (6.3)	
Malignancy, n (%)				1
Hodgkin lymphoma (HL)	18 (78.3)	32 (78.0)	50 (78.1)	
Peripheral T cell lymphoma	5 (21.7)	9 (22.0)	14 (21.9)	
Disease state prior to treatment, n (%)				0.523
Complete Remission (CR)	5 (21.7)	15 (36.6)	20 (31.3)	
Partial Remission (PR)	4 (17.4)	7 (17.1)	11 (17.2)	
Stable Disease (SD)	1 (4.3)	3 (7.3)	4 (6.3)	
Progressive Disease (PD)	13 (56.5)	16 (39.0)	29 (45.3)	
KPS score (median [range]) ¹	90.0 [70.0, 100.0]	90.0 [70.0, 100.0]	90.0 [70.0, 100.0]	0.824
HCT-CI score (median [range]) ²	2.0 [2.0, 5.0]	2 [2.0, 6.0]	2.0 [2.0, 6.0]	0.373
Prior lines of chemotherapy (median [range])	6.0 [2.0, 17.0]	4.0 [2.0, 10.0]	4.0 [2.0, 17.0]	0.017
CAR T lymphodepletion regimen, n (%)				0.120
Fludarabine/Bendamustine	15 (65.2)	22 (53.7)	37 (57.8)	
Fludarabine/Cyclophosphamide	1 (4.3)	2 (4.9)	3 (4.7)	
Bendamustine	4 (17.4)	3 (7.3)	7 (10.9)	
Post-HCT infusion	2 (8.7)	14 (34.1)	16 (26.0)	
Other	1 (4.3)	0 (0.0)	1 (1.6)	
HSCT before CAR T, n (%)	20 (87.0)	36 (87.8)	56 (87.5)	1
HSCT type				0.586
Allogenic	1 (4.3)	5 (12.2)	6 (9.4)	
Autologous	19 (82.6)	31 (75.6)	50 (78.1)	
Median Duration between HSCT and CAR T-cell infusion (Days, median [range])	1212.5 [21.0, 3655.0]	758.0 [16.0, 6186.0]	1087.0 [16.0, 6186.0]	0.095
Auto HSCT within 90 days of CAR T-cell infusion	10 (43.5)	19 (46.3)	29 (45.3)	1.000
HSCT within 1 year after CAR T, n (%)	0 (0)	0(0)	0 (0)	NA
Steroids (Day-30 through 1 year post-CAR T), n (%) ³ Antimicrobial prophylaxis	11 (47.8)	17 (41.5)	28 (43.8)	0.818
Fluoroquinolones	14 (60.9)	27 (65.9)	41 (64.1)	0.899
Fluconazole	14 (60.9)	24 (58.5)	28 (43.8)	1.000
Bactrim (trimethoprim-sulfamethoxazole)	10 (43.5)	19 (46.3)	29 (45.3)	1.000
Valacyclovir	16 (69.6)	32 (78.0)	48 (75.0)	0.652
Median ANC at Day -30 (median [range])	2.5 [1.1, 5.2]	4.0 [0.0, 40.8]	3.4 [0.0, 40.8]	0.004

Median ALC at Day -30 (median [range])	0.9 [0.2, 2.2]	0.7 [0.1, 3.4]	0.7 [0.1, 3.4]	0.407
ANC at lymphodepletion (median [range]) ⁴	3.1 [1.4, 5.8]	3.4 [1.0, 20.7]	3.2 [1.0, 20.7]	0.200
ALC at lymphodepletion (median [range]) ⁵	0.9 [0.1, 2.6]	0.6 [0.0, 3.3]	0.7 [0.0, 3.3]	0.315
Total days of neutropenia (median [range ^{])6}	0 [0, 27]	0 [0, 33]	0 [0, 33]	0.265
Total days of lymphopenia (median [range]) ⁷	7 [0, 115]	7 [0, 46]	7 [0, 115]	0.455
Patients with pre-treatment infection within 30 days prior to CAR-T, n (%)	0 (0.0)	3 (7.3)	3 (4.7)	0.476
Pre-CART infections by organism, n (%)				0.414
Bacterial	0 (0.0)	2 (66.7)	2 (66.7)	
Fungal	0 (0.0)	0 (0.0)	0 (0.0))	
Viral	0 (0.0)	1 (33.3)	1 (33.3)	
Cytokine-release syndrome (CRS), n (%)	6 (26.1)	10 (24.4)	16 (25.0)	1
CRS grade, n (%)				0.979
Grade 1	4 (17.4)	7 (17.1)	11 (17.2)	
Grade 2	2 (8.7)	3 (7.3)	5 (7.8)	
CRS treatment (Tocilizumab), n (%) ⁸	2 (8.7)	3 (7.3)	5 (7.8)	1
Neurotoxicity (ICANS), n (%)	0 (0.0)	0 (0.0)	0 (0.0)	NA
ICU Admission (within 30 days of CAR-T infusion, n (%))	1 (4.3)	2 (4.9)	3 (4.7)	1
Relapse within 1 year after CAR T-cell therapy, n (%)	16 (69.6)	21 (51.2)	37 (58)	0.245
Cause of Death				0.388
Infection-related	3 (37.5)	2 (40.0)	5 (8)	
Relapse-related	5 (62.5)	2 (40.0)	7 (11)	
Unknown	0 (0.0)	1 (20.0)	1 (2)	
Mortality within 30 days of CAR T, n (%)	0 (0.0)	0 (0.0)	0 (0.0)	NA

*28 total infections in 23 patients during the follow-up period. Three patients had two infections; one patient had three infections. ¹KPS, Karnofsky Performance Status

²HCT-CI, Hematopoietic Stem Cell Transplant-specific Comorbidity Index

³HSCT, Hematopoietic Stem Cell Transplant

⁴Steroids (30 days prior to CAR T through 1 year after CAR T) include dexamethasone, prednisone, and methylprednisolone

⁵ANC, absolute neutrophil count

⁶ALC, absolute lymphocyte count

⁷ Neutropenia defined as ANC <500 cells/mm³

⁸Lymphopenia defined as ALC <200 cells/mm³

⁹CRS was only treated with Tocilizumab in this cohort

Figure 1. **Greater numbers of viral infections were observed after CD30. CAR T-cell therapy compared to bacterial infections.** Cumulative incidence curves demonstrating time to first infections in the one year after CD30 CAR T-cell therapy, including all infections (A), only viral infections (B), and only bacterial infections (C).







A.



Table 2. Infectious organisms subdivided by bacterial, viral, or fungal etiology after (A) CD30 CAR T-cell therapy or (B) CD19 CAR T-cell therapy. Number in parathesis indicates total number of infections for causative organism. EBV = Epstein Barr Virus. HSV = Herpes Simplex Virus. RSV = Respiratory Syncytial Virus. SARS-CoV-2 = COVID-19. VZV = Varicella Zoster Virus.

А.				
Infections after CD30 CAR T-cell therapy				
Bacterial	Viral	Fungal		
Escherichia coli	Coronavirus NL63	Pneumocystis jirovecii		
Serratia marcescens	EBV (2)			
Staphylococcus aureus (2)	HSV			
Staphylococcus epidermidis	Influenza A			
Streptococcus dysgalactiae	Rhinovirus (6)			
	RSV (2)			
	SARS-CoV-2 (6)			
	VZV (5)			

B.

Infections after CD19 CAR T-cell therapy			
Bacterial	Viral	Fungal	
Bacterial vaginosis	HSV (3)	Fusarium species	
Campylobacter spp.	Norovirus	Pneumocystis jirovecii (2)	
Citrobacter braakii	Rhinovirus (3)		
Enterococcus faecalis	RSV		
Escherichia coli	SARS-CoV-2 (4)		
Klebsiella pneumoniae (3)			
Staphylococcus aureus			
Serratia marcescens			
Staphylococcus epidermidis			
Streptococcus agalactiae			
Streptococcus mitis			

Figure 3. More severe infections and more infections of bacterial origin were observed after CD19.CAR T-cell therapy compared to CD30.CAR T-cell therapy. Number of infections including bacterial, viral, and fungal etiologies of different severities occurring during the first 1 year following CAR T-cell therapy, broken into infection periods (0-28, 29-90, and 91-365 days), and compared between anti-CD30 CAR-T therapy (A) and anti-CD19 CAR-T therapy (B). Of note, two infections in B are not shown as their severity was determined as "unknown". All other available data are shown, regardless of relapse.



Figure 4. Immune recovery after CD30 CAR T-cell therapy demonstrates rare differences between infected and uninfected patients within 1 year after infusion. Absolute neutrophil counts (ANC, Figure 4A) and absolute lymphocyte counts (ALC; Figure 4B) are demonstrated at timepoints relative to the day of CAR-T infusion. Comparisons between infected and uninfected patients were performed using the Wilcoxon rank-sum test, with p-value <0.05 being given one star and p-value <0.01 being given two stars at the top of the plot.



Figure 5. Immune recovery after CAR T-cell therapy demonstrates significant differences between CD30 and CD19 products within 1 year after infusion. Absolute neutrophil counts (ANC, Figure 5A) and absolute lymphocyte counts (ALC; Figure 4B) are demonstrated at timepoints relative to the day of CAR-T infusion. Comparisons between CD30 and CD19 recipients were performed using the Wilcoxon rank-sum test, with p-value <0.05 as one star, p-value <0.01 with two stars, and p-value <0.005 with three stars at the top of the plot.

